human
epitheli
cell
hela
african
green
monkey
fibroblast
vero
maintain
dulbecco
modifi
eagl
medium
supplement
fetal
calf
serum
penicillinstreptomycin
uml
niv
isol
genbank
access
number
hev
obtain
porton
laboratori
porton
unit
kingdom
prepar
inserm
jean
biosafeti
level
laboratori
lyon
franc
infect
vero
cell
paavhcmvmseap
paavgfp
vector
plasmid
encod
mousesecret
embryon
alkalin
phosphatas
mseap
enhanc
green
fluoresc
protein
egfp
complementari
dna
respect
driven
cytomegaloviru
cmv
promot
paavhcmvnivg
vector
plasmid
obtain
insert
nivg
express
cassett
deriv
phcmvnivg
plasmid
plasmid
phcmvnivg
plasmid
encod
solubl
niv
g
gs
protein
stock
aav
vector
particl
gener
calcium
phosphat
transfect
cell
describ
previous
helper
plasmid
use
product
kind
gift
p
moullier
inserm
franc
kind
gift
j
wilson
univers
pennsylvania
vector
core
vector
particl
purifi
cesium
chlorid
gradient
number
genom
particl
per
millilit
titer
quantit
revers
transcript
polymeras
chain
reaction
qrtpcr
anim
handl
strict
accord
good
anim
practic
defin
french
nation
charter
ethic
anim
experiment
balbc
male
mice
inject
aav
vector
either
intramuscularli
genom
particl
intraderm
genom
particl
golden
hamster
immun
intramuscularli
genom
particl
challeng
niv
hev
anim
hous
ventil
contain
laboratori
inject
intraperiton
particleform
unit
niv
hev
anim
observ
daili
appear
clinic
sign
bodi
weight
dyspnea
tremor
limb
paralysi
immedi
euthan
case
symptom
anim
surviv
euthan
day
challeng
stock
solubl
niv
g
protein
produc
transfect
cell
phcmvnivg
plasmid
elisa
ninta
plate
qiagen
coat
overnight
either
solubl
niv
g
protein
control
supernat
dilut
sera
ad
hour
room
temperatur
follow
incub
secondari
antibodi
hour
room
temperatur
plate
incub
substrat
sigmaaldrich
optic
densiti
measur
nm
nm
secondari
antibodi
southern
biotech
use
horseradish
peroxidas
hrp
antimous
immunoglobulin
g
igg
hrpgoat
antimous
hrpgoat
antimous
hrpgoat
antihamst
igg
hrpmous
antihamst
hrpmous
antihamst
niv
vlp
produc
previous
describ
szecsi
et
al
briefli
niv
vlp
produc
cell
transient
transfect
plasmid
plasmid
code
vesicular
stomat
viru
g
protein
use
gener
control
vlp
vlp
contain
supernat
harvest
hour
transfect
concentr
titer
neutral
assay
serial
dilut
sera
mix
vlp
incub
hour
ad
hela
cell
transduct
effici
determin
hour
later
measur
percentag
gfpposit
cell
use
fluorescenceactiv
cell
sort
analysi
niv
hev
neutral
ab
nab
assay
use
dilut
serum
describ
previous
cytopath
effect
reveal
stain
cell
crystal
violet
titer
defin
reciproc
last
dilut
complet
inhibit
cytopath
effect
rna
purifi
tissu
accord
manufactur
instruct
rneasi
mini
kit
qiagen
treat
turbo
dnasei
ambion
life
technolog
revers
transcrib
use
qscript
complementari
dna
super
mix
quanta
bioscienc
total
genom
dna
extract
tissu
use
wizard
sv
genom
dna
purif
system
promega
qrtpcr
reaction
conduct
ng
complementari
dna
genom
dna
use
faststart
univers
sybr
green
master
reagent
roch
diagnost
qrtpcr
run
step
one
plu
real
time
pcr
system
appli
biosystem
sequenc
primer
avail
request
sampl
run
duplic
result
analyz
use
abi
stepon
softwar
data
express
mean
standard
error
mean
statist
analys
perform
use
student
test
analysi
varianc
graphpad
softwar
differ
consid
statist
signific
p
first
part
studi
focus
character
aavinduc
antiniv
g
immun
respons
mice
compar
sever
vaccin
condit
aav
serotyp
chosen
abil
effici
transduc
muscl
broad
tropism
recent
isol
variant
demonstr
superior
capac
induc
cellular
immun
respons
transgen
product
intramuscular
intraderm
inject
rout
antiniv
g
ab
detect
week
prime
inject
figur
level
peak
week
significantli
chang
week
prime
except
inject
intramuscularli
intraderm
respect
gener
humor
respons
gener
intraderm
inject
significantli
lower
observ
intramuscular
inject
minor
differ
observ
among
aav
serotyp
contrast
inject
intramuscular
rout
superior
serotyp
term
kinet
ab
level
figur
isotyp
detect
aav
serotyp
independ
inject
rout
figur
howev
inject
via
intramuscular
rout
induc
domin
respons
product
nab
niv
follow
kinet
strongest
rapid
respons
obtain
inject
intramuscular
rout
data
shown
examin
possibl
enhanc
humor
respons
second
aav
inject
anim
prime
either
receiv
second
inject
week
interestingli
moder
increas
igg
nab
titer
observ
week
boost
inject
figur
also
boost
alter
domin
respons
observ
intramuscular
inject
data
shown
importantli
detect
antiaav
capsid
nab
confirm
ineffici
boost
effect
due
priminginjectioninduc
crossneutr
respons
vector
supplementari
figur
persist
express
aavencod
transgen
may
import
induct
longlast
immun
respons
gener
transgenespecif
immun
may
result
elimin
aavtransduc
cell
analyz
persist
vector
time
compar
vector
encod
gfp
report
persist
express
transgen
time
measur
aavgfp
dna
copi
inject
muscl
indic
initi
drop
week
inject
number
aavgfp
copi
remain
stabl
least
week
figur
expect
followup
evalu
aavnivg
dna
indic
increas
elimin
vector
dna
week
inject
compar
aavgfp
sampl
howev
interestingli
aavnivg
dna
level
remain
stabl
thereaft
quantif
niv
g
rna
week
inject
indic
transgen
still
express
signific
level
figur
result
confirm
aav
vector
dna
still
present
continu
express
transgen
week
inject
next
evalu
aav
vaccin
golden
hamster
anim
model
current
use
studi
henipaviru
pathogenesi
anim
inject
nivg
vector
via
intramuscular
rout
follow
antiniv
g
igg
respons
indic
differ
kinet
observ
mice
figur
earlier
onset
ab
product
week
peak
week
inject
progress
declin
week
remain
stabl
thereaft
moreov
observ
mice
domin
respons
induc
data
shown
nab
level
challeng
follow
kinet
igg
level
howev
nab
level
remain
stabl
least
week
inject
suggest
persist
induct
highaffin
nab
figur
verifi
level
ab
respons
achiev
aav
vaccin
suffici
protect
anim
challeng
niv
vaccin
anim
inject
intraperiton
lethal
dose
wildtyp
niv
week
vaccin
control
anim
inject
develop
clinic
sign
infect
day
challeng
contrast
vaccin
anim
surviv
end
experi
without
appear
clinic
sign
figur
level
antiniv
nab
analyz
use
differ
neutral
assay
adapt
laboratori
base
inhibit
cytopath
effect
induc
wildtyp
niv
vero
cell
see
materi
method
previou
comparison
neutral
assay
indic
strong
correl
method
even
antiniv
nab
titer
calcul
use
wildtyp
niv
averag
inferior
observ
use
niv
vlp
supplementari
figur
explain
prechalleng
nab
level
nearli
undetect
wildtyp
niv
assay
vaccin
anim
tabl
despit
detect
nab
niv
vlp
assay
figur
analysi
postchalleng
sera
indic
vaccin
anim
develop
detect
anamnest
respons
tabl
expect
niv
rna
found
lung
spleen
lower
level
brain
control
anim
contrast
undetect
organ
vaccin
anim
includ
anim
figur
tabl
immunohistochemistri
analysi
confirm
absenc
detect
niv
antigen
organ
vaccin
anim
supplementari
figur
studi
shown
vivo
deliveri
solubl
hev
g
protein
result
crossprotect
niv
contrast
niv
g
protein
gener
consid
unabl
induc
crossprotect
immun
hev
evalu
anim
vaccin
challeng
hev
follow
anim
indic
surviv
challeng
figur
expect
none
vaccin
anim
detect
antihev
crossneutr
nab
challeng
tabl
challeng
surviv
anim
anim
develop
antihev
nab
howev
hev
rna
detect
organ
anim
surviv
challeng
tabl
figur
similarli
hev
antigen
detect
immunohistochemistri
analysi
supplementari
figur
togeth
result
strongli
suggest
singl
inject
vector
induc
steril
immun
niv
infect
well
crossprotect
immun
suffici
protect
anim
lethal
challeng
hev
strategi
henipaviru
infect
either
prevent
therapeut
virus
caus
sporad
outbreak
therapeut
treatment
viru
contact
seem
suitabl
strategi
accordingli
recent
effort
focus
develop
monoclon
antibodi
capabl
recogn
g
glycoprotein
niv
hev
howev
henipavirus
rapidli
replic
spread
entri
strategi
narrow
therapeut
window
consequ
prevent
vaccin
remain
suitabl
altern
particularli
protect
peopl
may
contact
infect
anim
suscept
livestock
vaccin
strategi
henipaviru
infect
mostli
base
repeat
inject
high
dose
hev
g
protein
mix
adjuv
induc
protect
humor
respons
altern
strategi
base
viral
vector
express
henipaviru
antigen
also
report
except
canarypox
viru
vector
current
use
human
sever
argument
favor
use
aav
vector
vaccin
henipavirus
first
aav
vector
deriv
nonpathogen
viru
lack
toxic
document
sever
preclin
clinic
studi
second
wide
tropism
aav
exist
sever
aav
serotyp
allow
effici
gene
transfer
via
differ
inject
rout
numer
anim
speci
final
previou
studi
suggest
singl
inject
aav
vector
result
strong
sustain
product
ab
transgen
product
first
part
studi
focus
character
aavinduc
humor
respons
found
vector
inject
intramuscularli
effici
produc
antiniv
g
ab
figur
intramuscular
intraderm
rout
kinet
antiniv
g
ab
character
delay
detect
week
inject
peak
product
week
inject
unusu
lag
phase
previous
document
studi
like
reflect
time
requir
convers
singlestrand
aav
vector
genom
doublestrand
dna
form
abl
express
transgen
use
doublestrand
aav
vector
circumv
ratelimit
step
acceler
synthesi
antigen
may
improv
kinet
ab
product
anoth
major
characterist
aavinduc
humor
respons
mice
detect
high
level
extend
period
figur
mani
group
similarli
document
persist
aavinduc
humor
respons
analysi
vector
persist
express
transduc
tissu
suggest
persist
ab
level
may
due
continu
express
transgen
figur
contrast
declin
igg
level
week
inject
hamster
could
due
reduc
vector
persist
anim
speci
figur
futur
studi
compar
rang
aav
dose
hamster
mice
indic
whether
differ
link
host
speci
vector
dose
final
observ
boost
inject
altern
aav
serotyp
mice
significantli
enhanc
ab
level
figur
contrast
sever
studi
document
possibl
boost
aavinduc
humor
respons
use
adenovir
vector
possibl
booster
effect
could
observ
boost
perform
later
time
humor
respons
induc
prime
inject
declin
addit
studi
also
perform
determin
whether
observ
transpos
anim
speci
second
part
studi
analyz
whether
singl
aav
inject
suffici
protect
anim
lethal
challeng
henipavirus
vaccin
anim
protect
lethal
challeng
niv
figur
absenc
niv
antigen
supplementari
figur
rna
figur
tabl
tissu
well
moder
anamnest
respons
observ
anim
tabl
strongli
suggest
mode
vaccin
induc
steril
immun
far
vaccin
studi
report
abil
induc
steril
immun
particular
variabl
result
obtain
use
solubl
hev
g
protein
suggest
high
repeat
dose
antigen
coupl
adjuv
may
complet
prevent
viru
replic
induct
steril
immun
singl
aav
inject
may
reflect
uniqu
contribut
made
vaccin
approach
certainli
deserv
futur
investig
niv
hev
g
protein
homolog
level
homolog
suggest
crossneutr
respons
induc
accordingli
ab
hev
g
protein
report
crossneutr
niv
contrast
niv
g
protein
consid
unabl
induc
effici
crossprotect
respons
vivo
notion
mostli
support
vitro
neutral
assay
show
antiniv
g
ab
effici
neutral
hev
howev
potenti
crossprotect
effect
antiniv
g
respons
hev
evalu
far
studi
observ
anim
vaccin
aavnivg
surviv
challeng
hev
figur
interest
result
suggest
low
level
crossneutr
ab
hev
detect
neutral
assay
tabl
may
induc
vaccin
altern
possibl
protect
confer
cellmedi
immun
respons
even
though
cellular
respons
henipaviru
glycoprotein
character
far
cellular
particularli
tcell
respons
may
induc
play
role
protect
anim
accordingli
induct
adapt
thelper
immun
respons
niv
g
suggest
occur
follow
inject
canarypox
viru
vector
encod
niv
g
pig
interestingli
intramuscular
inject
induc
domin
respons
mice
hamster
observ
aav
serotyp
via
intraderm
rout
figur
result
suggest
capsid
serotyp
may
induc
antiniv
g
thelper
immun
respons
challeng
perform
earlier
time
point
adopt
transfer
cell
indic
extent
cellular
respons
niv
g
protect
viral
infect
studi
includ
serotyp
select
abil
induc
qualit
quantit
superior
cellular
respons
togeth
result
demonstr
aav
vector
constitut
power
genet
platform
vivo
express
henipaviru
antigen
use
explor
immunolog
basi
antihenipaviru
vaccin
develop
new
prophylact
strategi
